Class information for: |
Basic class information |
Hierarchy of classes |
The table includes all classes above and classes immediately below the current class. |
Cluster id | Level | Cluster label | #P |
---|---|---|---|
10 | 4 | IMMUNOLOGY//TRANSPLANTATION//RHEUMATOLOGY | 1369268 |
580 | 3 | MULTIPLE MYELOMA//THALIDOMIDE//MYELOMA | 16076 |
600 | 2 | MULTIPLE MYELOMA//MYELOMA//BORTEZOMIB | 14474 |
943 | 1 | MULTIPLE MYELOMA//LENALIDOMIDE//BORTEZOMIB | 2978 |
Terms with highest relevance score |
rank | Category | termType | chi_square | shrOfCwithTerm | shrOfTermInClass | termInClass |
---|---|---|---|---|---|---|
1 | MULTIPLE MYELOMA | authKW | 2641181 | 46% | 18% | 1372 |
2 | LENALIDOMIDE | authKW | 1667733 | 13% | 42% | 375 |
3 | BORTEZOMIB | authKW | 1168639 | 15% | 25% | 439 |
4 | THALIDOMIDE | authKW | 903472 | 13% | 22% | 381 |
5 | POMALIDOMIDE | authKW | 575523 | 3% | 71% | 77 |
6 | MYELOMA UNIT | address | 487132 | 3% | 58% | 80 |
7 | MYELOMA | authKW | 419091 | 9% | 15% | 269 |
8 | ELOTUZUMAB | authKW | 371429 | 1% | 95% | 37 |
9 | IMMUNOMODULATORY DRUGS | authKW | 266349 | 2% | 38% | 66 |
10 | CARFILZOMIB | authKW | 230199 | 2% | 40% | 54 |
Web of Science journal categories |
chi_square_rank | Category | chi_square | shrOfCwithTerm | shrOfTermInClass | termInClass |
---|---|---|---|---|---|
1 | Hematology | 95909 | 54% | 1% | 1613 |
2 | Oncology | 22598 | 45% | 0% | 1353 |
3 | Transplantation | 3502 | 7% | 0% | 221 |
4 | Immunology | 558 | 8% | 0% | 247 |
5 | Medicine, General & Internal | 294 | 6% | 0% | 187 |
6 | Pharmacology & Pharmacy | 122 | 6% | 0% | 193 |
7 | Medicine, Research & Experimental | 44 | 3% | 0% | 81 |
8 | Health Care Sciences & Services | 37 | 1% | 0% | 36 |
9 | Nursing | 26 | 1% | 0% | 26 |
10 | Medical Laboratory Technology | 18 | 1% | 0% | 20 |
Address terms |
chi_square_rank | term | chi_square | shrOfCwithTerm | shrOfTermInClass | termInClass |
---|---|---|---|---|---|
1 | MYELOMA UNIT | 487132 | 3% | 58% | 80 |
2 | AZIENDA OSPED S GIOVANNI BATTISTA | 158882 | 1% | 52% | 29 |
3 | MYELOMA THER Y | 155644 | 2% | 20% | 74 |
4 | SERAGNOLI HEMATOL | 155478 | 1% | 57% | 26 |
5 | HEMATOL | 150009 | 29% | 2% | 859 |
6 | AZIENDA OSPED UNIV CITTA SALUTE SCI TORINO | 127195 | 1% | 52% | 23 |
7 | JEROME LIPPER MULTIPLE MYELOMA | 119280 | 2% | 20% | 57 |
8 | JOHN THEURER CANC | 96682 | 1% | 23% | 40 |
9 | MYELOMA PROGRAM | 93303 | 1% | 42% | 21 |
10 | CLIN EMATOL | 91626 | 1% | 23% | 37 |
Journals |
chi_square_rank | term | chi_square | shrOfCwithTerm | shrOfTermInClass | termInClass |
---|---|---|---|---|---|
1 | CLINICAL LYMPHOMA MYELOMA & LEUKEMIA | 68764 | 2% | 9% | 74 |
2 | CLINICAL LYMPHOMA & MYELOMA | 35616 | 1% | 10% | 33 |
3 | EUROPEAN JOURNAL OF HAEMATOLOGY | 25920 | 3% | 3% | 98 |
4 | LEUKEMIA & LYMPHOMA | 21218 | 4% | 2% | 125 |
5 | BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION | 20010 | 3% | 2% | 78 |
6 | EXPERT REVIEW OF HEMATOLOGY | 19047 | 1% | 5% | 33 |
7 | BONE MARROW TRANSPLANTATION | 18436 | 4% | 1% | 125 |
8 | BLOOD CANCER JOURNAL | 18041 | 1% | 7% | 24 |
9 | BRITISH JOURNAL OF HAEMATOLOGY | 17496 | 5% | 1% | 151 |
10 | BLOOD | 15057 | 8% | 1% | 224 |
Author Key Words |
chi_square_rank | term | chi_square | shrOfCwithTerm | shrOfTermInClass | termInClass | LCSH search | Wikipedia search |
---|---|---|---|---|---|---|---|
1 | MULTIPLE MYELOMA | 2641181 | 46% | 18% | 1372 | Search MULTIPLE+MYELOMA | Search MULTIPLE+MYELOMA |
2 | LENALIDOMIDE | 1667733 | 13% | 42% | 375 | Search LENALIDOMIDE | Search LENALIDOMIDE |
3 | BORTEZOMIB | 1168639 | 15% | 25% | 439 | Search BORTEZOMIB | Search BORTEZOMIB |
4 | THALIDOMIDE | 903472 | 13% | 22% | 381 | Search THALIDOMIDE | Search THALIDOMIDE |
5 | POMALIDOMIDE | 575523 | 3% | 71% | 77 | Search POMALIDOMIDE | Search POMALIDOMIDE |
6 | MYELOMA | 419091 | 9% | 15% | 269 | Search MYELOMA | Search MYELOMA |
7 | ELOTUZUMAB | 371429 | 1% | 95% | 37 | Search ELOTUZUMAB | Search ELOTUZUMAB |
8 | IMMUNOMODULATORY DRUGS | 266349 | 2% | 38% | 66 | Search IMMUNOMODULATORY+DRUGS | Search IMMUNOMODULATORY+DRUGS |
9 | CARFILZOMIB | 230199 | 2% | 40% | 54 | Search CARFILZOMIB | Search CARFILZOMIB |
10 | DARATUMUMAB | 226866 | 1% | 79% | 27 | Search DARATUMUMAB | Search DARATUMUMAB |
Core articles |
The table includes core articles in the class. The following variables is taken into account for the relevance score of an article in a cluster c: (1) Number of references referring to publications in the class. (2) Share of total number of active references referring to publications in the class. (3) Age of the article. New articles get higher score than old articles. (4) Citation rate, normalized to year. |
Classes with closest relation at Level 1 |